LeukoScan
sulesomab
Table of contents
Overview
The marketing authorisation for LeukoScan has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
LeukoScan
|
| Agency product number |
EMEA/H/C/000111
|
| Active substance |
sulesomab
|
| International non-proprietary name (INN) or common name |
sulesomab
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
VO4D
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Immunomedics GmbH
|
| Revision |
7
|
| Date of issue of marketing authorisation valid throughout the European Union |
14/02/1997
|
| Contact address |
Otto-Röhm-Straße 69
D-64293 Darmstadt Germany |
Product information
18/01/2017 LeukoScan - EMEA/H/C/000111 - IAIN/0024/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Diagnostic agents
Therapeutic indication
This medicinal product is for diagnostic use only.
LeukoScan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.
LeukoScan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.